Polymorphisms in Thioredoxin Reductase and Selenoprotein K Genes and Selenium Status Modulate Risk of Prostate Cancer

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Méplan, Catherine ^a   Rohrmann, Sabine ^b,c   Steinbrecher, Astrid ^c   Schomburg, Lutz ^d   Jansen, Eugène ^e   Linseisen, Jakob ^c,f   Hesketh, John ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE PEROXIDASE; SELENIUM; SELENOPROTEIN; SELENOPROTEIN K; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DIET; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; ONCOGENE; PROSTATE CANCER; RISK ASSESSMENT; SBP2 GENE; SELENOPROTEIN K GENE; SELK GENE; SEPS1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; THIOREDOXIN REDUCTASE GENE; TXNRD1 GENE; TXNRD2 GENE;

CASE-CONTROL STUDIES; DISEASE PROGRESSION; GENOTYPE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MODELS, GENETIC; MODELS, STATISTICAL; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; SELENIUM; SELENOPROTEIN P; SELENOPROTEINS; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84868322165     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048709     Document Type: Article

References (40)

1. Fairweather-Tait SJ, Bao Y, Broadley MR, Collings R, Ford D, et al. (2011) Selenium in human health and disease. Antioxid Redox Signal 14: 1337-1383.
2. Rayman MP, (2012) Selenium and human health. Lancet 379: 1256-1268.
3. Whanger PD, (2004) Selenium and its relationship to cancer: an update dagger. Br J Nutr 91: 11-28.
4. Peters U, Takata Y, (2008) Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res 52: 1261-1272.
5. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Jama 276: 1957-1963.
6. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama 301: 39-51.
7. Dunn BK, Taylor PR (2012) Prostate Cancer Prevention and the Selenium and Vitamin E Cancer Prevention Trial (SELECT): A Selenium perspective. In: Hatfield DL, Berry MJ, Gladyshev VN, editors. Selenium-Its Molecular Biology and Role in Human Health, 3rd edition. Berlin: Springer. 297-311.
8. Lobanov AV, Hatfield DL, Gladyshev VN, (2009) Eukaryotic selenoproteins and selenoproteomes. Biochim Biophys Acta 1790: 1424-1428.
9. Zhuo P, Diamond AM, (2009) Molecular mechanisms by which selenoproteins affect cancer risk and progression. Biochim Biophys Acta 1790: 1546-1554.
10. Papp LV, Holmgren A, Khanna KK, (2010) Selenium and selenoproteins in health and disease. Antioxid Redox Signal 12: 793-795.
11. Ashton K, Hooper L, Harvey LJ, Hurst R, Casgrain A, et al. (2009) Methods of assessment of selenium status in humans: a systematic review. Am J Clin Nutr 89: 2025S-2039S.
12. Xia Y, Hill KE, Li P, Xu J, Zhou D, et al. (2010) Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr 92: 525-531.
13. Steinbrecher A, Meplan C, Hesketh J, Schomburg L, Endermann T, et al. (2010) Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev 19: 2958-2968.
14. Gonzalez-Moreno O, Boque N, Redrado M, Milagro F, Campion J, et al. (2011) Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage. Prostate 71: 824-834.
15. Hesketh J, (2008) Nutrigenomics and selenium: gene expression patterns, physiological targets, and genetics. Annu Rev Nutr 28: 157-177.
16. Schomburg L, (2010) Genetics and phenomics of selenoenzymes-how to identify an impaired biosynthesis? Mol Cell Endocrinol 322: 114-124.
17. Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, et al. (2010) A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila) 3: 604-610.
18. Cooper ML, Adami HO, Gronberg H, Wiklund F, Green FR, et al. (2008) Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res 68: 10171-10177.
19. Boeing H, Korfmann A, Bergmann MM, (1999) Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab 43: 205-215.
20. Paglia DE, Valentine WN, (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158-169.
21. Sieniawska CE, Meniskov R, Delves HT, (1999) Determination of total selenium in serum, whole blood and erythrocytes by ICP-MS. J Anal Atomic Spectrom 14: 109-112.
22. Hollenbach B, Morgenthaler NG, Struck J, Alonso C, Bergmann A, et al. (2008) New assay for the measurement of selenoprotein P as a sepsis biomarker from serum. J Trace Elem Med Biol 22: 24-32.
23. Knoblauch H, Bauerfeind A, Toliat MR, Becker C, Luganskaja T, et al. (2004) Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet 13: 993-1004.
24. Weng L, Macciardi F, Subramanian A, Guffanti G, Potkin SG, et al. (2011) SNP-based pathway enrichment analysis for genome-wide association studies. BMC Bioinformatics 12: 99.
25. Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, et al. (2010) Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 19: 2869-2876.
26. Shchedrina VA, Everley RA, Zhang Y, Gygi SP, Hatfield DL, et al. (2011) Selenoprotein K binds multiprotein complexes and is involved in the regulation of endoplasmic reticulum homeostasis. J Biol Chem 286: 42937-42948.
27. Kumaraswamy E, Malykh A, Korotkov KV, Kozyavkin S, Hu Y, et al. (2000) Structure-expression relationships of the 15-kDa selenoprotein gene. Possible role of the protein in cancer etiology. J Biol Chem 275: 35540-35547.
28. Mohler JL, Morris TL, Ford OH 3rd, Alvey RF, Sakamoto C, et al (2002) Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate 51: 247-255.
29. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM, (2003) The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 23: 2425-2433.
30. Cai W, Zhang L, Song Y, Wang B, Zhang B, et al. (2012) Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic Biol Med 52: 257-265.
31. Urig S, Becker K, (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 16: 452-465.
32. Verma S, Hoffmann FW, Kumar M, Huang Z, Roe K, et al. (2011) Selenoprotein K knockout mice exhibit deficient calcium flux in immune cells and impaired immune responses. J Immunol 186: 2127-2137.
33. Vanden Abeele F, Skryma R, Shuba Y, Van Coppenolle F, Slomianny C, et al. (2002) Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. Cancer Cell 1: 169-179.
34. Meplan C, Crosley LK, Nicol F, Beckett GJ, Howie AF, et al. (2007) Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). Faseb J 21: 3063-3074.
35. Meplan C, Crosley LK, Nicol F, Horgan GW, Mathers JC, et al. (2008) Functional effects of a common single-nucleotide polymorphism (GPX4c718t) in the glutathione peroxidase 4 gene: interaction with sex. Am J Clin Nutr 87: 1019-1027.
36. Meplan C, Nicol F, Burtle BT, Crosley LK, Arthur JR, et al. (2009) Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid Redox Signal 11: 2631-2640.
37. Schomburg L, Schweizer U, (2009) Hierarchical regulation of selenoprotein expression and sex-specific effects of selenium. Biochim Biophys Acta 1790(11): 1453-1462.
38. Hesketh J, Meplan C (2011) Transcriptomics and functional genetic polymorphisms as biomarkers of micronutrient function: focus on selenium as an exemplar. Proc Nutr Soc: 1-9.
39. Kicinski M, Vangronsveld J, Nawrot TS, (2011) An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS ONE 6: e27130.
40. Platz EA, (2010) Is prostate cancer prevention with selenium all in the genes? Cancer Prev Res (Phila) 3: 576-578.